PMID- 38347461
OWN - NLM
STAT- MEDLINE
DCOM- 20240214
LR  - 20240215
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 24
IP  - 1
DP  - 2024 Feb 12
TI  - Efficacy and safety of temozolomide-based regimens in advanced pancreatic 
      neuroendocrine tumors: a systematic review and meta-analysis.
PG  - 192
LID - 10.1186/s12885-024-11926-2 [doi]
LID - 192
AB  - BACKGROUND: Recent advances in the management of pancreatic neuroendocrine tumors 
      (pNETs) highlight the potential benefits of temozolomide, an alkylating agent, 
      for these patients. In this meta-analysis, we aimed to assess the outcome of 
      temozolomide, alone or in combination with other anticancer medications in 
      patients with advanced pNET. METHODS: Online databases of PubMed, Web of Science, 
      Embase, the Cochrane Library, and ClinicalTrials.gov were searched systematically 
      for clinical trials that reported the efficacy and safety of temozolomide in 
      patients with advanced pNET. Random-effect model was utilized to estimate pooled 
      rates of outcomes based on Response Evaluation Criteria in Solid Tumors criteria, 
      biochemical response, and adverse events (AEs). RESULTS: A total of 14 studies, 
      providing details of 441 individuals with advanced pNET, were included. The 
      quantitative analyses showed a pooled objective response rate (ORR) of 41.2% (95% 
      confidence interval, CI, of 32.4%-50.6%), disease control rate (DCR) of 85.3% 
      (95% CI of 74.9%-91.9%), and a more than 50% decrease from baseline chromogranin 
      A levels of 44.9% (95% CI of 31.6%-49.0%). Regarding safety, the results showed 
      that the pooled rates of nonserious AEs and serious AEs were 93.8% (95% CI of 
      88.3%-96.8%) and 23.7% (95% CI of 12.0%-41.5%), respectively. The main severe AEs 
      encompassed hematological toxicities. CONCLUSIONS: In conclusion, our 
      meta-analysis suggests that treatment with temozolomide, either as a monotherapy 
      or in combination with other anticancer treatments might be an effective and 
      relatively safe option for patients with advanced locally unresectable and 
      metastatic pNET. However, additional clinical trials are required to further 
      strengthen these findings. This study has been registered in PROSPERO 
      (CRD42023409280).
CI  - (c) 2024. The Author(s).
FAU - Taherifard, Erfan
AU  - Taherifard E
AD  - Department of Medicine, Division of Hematology & Oncology, University of 
      Pittsburgh Medical Center, Pittsburgh, PA, USA.
FAU - Bakhtiar, Muhammad
AU  - Bakhtiar M
AD  - Department of Medicine, Division of Hematology & Oncology, University of 
      Pittsburgh Medical Center, Pittsburgh, PA, USA.
FAU - Mahnoor, Mahnoor
AU  - Mahnoor M
AD  - Department of Medicine, Division of Hematology & Oncology, University of 
      Pittsburgh Medical Center, Pittsburgh, PA, USA.
FAU - Ahmed, Rabeea
AU  - Ahmed R
AD  - Department of Medicine, Division of Hematology & Oncology, University of 
      Pittsburgh Medical Center, Pittsburgh, PA, USA.
FAU - Cavalcante, Ludimila
AU  - Cavalcante L
AD  - Novant Health Cancer Institute, Charlotte, NC, USA.
FAU - Zhang, Janie
AU  - Zhang J
AD  - Department of Medicine, Division of Hematology & Oncology, University of 
      Pittsburgh Medical Center, Pittsburgh, PA, USA.
AD  - UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
FAU - Saeed, Anwaar
AU  - Saeed A
AD  - Department of Medicine, Division of Hematology & Oncology, University of 
      Pittsburgh Medical Center, Pittsburgh, PA, USA. saeeda3@upmc.edu.
AD  - UPMC Hillman Cancer Center, Pittsburgh, PA, USA. saeeda3@upmc.edu.
LA  - eng
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20240212
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - Humans
MH  - Temozolomide/adverse effects
MH  - *Neuroendocrine Tumors/drug therapy/pathology
MH  - Response Evaluation Criteria in Solid Tumors
MH  - *Pancreatic Neoplasms/drug therapy/pathology
MH  - *Neuroectodermal Tumors, Primitive
PMC - PMC10860315
OTO - NOTNLM
OT  - Adverse reactions
OT  - Drug-related side effects
OT  - Neuroendocrine tumors
OT  - Pancreatic neoplasms
OT  - Response evaluation criteria in solid tumors
OT  - Temozolomide
COIS- A.S. reports research grants (to institution) from AstraZeneca, Bristol Myers 
      Squibb, Merck, Clovis, Exelixis, Actuate Therapeutics, Incyte Corporation, 
      Daiichi Sankyo, Five Prime Therapeutics, Amgen, Innovent Biologics, Dragonfly 
      Therapeutics, KAHR Medical, and BioNtech and advisory board fees from 
      AstraZeneca, Bristol Myers Squibb, Exelixis, Pfizer, and Daiichi Sankyo. The 
      remaining authors have no relevant financial or non-financial interests to 
      disclose.
EDAT- 2024/02/13 00:42
MHDA- 2024/02/13 06:45
PMCR- 2024/02/12
CRDT- 2024/02/12 23:40
PHST- 2023/12/05 00:00 [received]
PHST- 2024/01/27 00:00 [accepted]
PHST- 2024/02/13 06:45 [medline]
PHST- 2024/02/13 00:42 [pubmed]
PHST- 2024/02/12 23:40 [entrez]
PHST- 2024/02/12 00:00 [pmc-release]
AID - 10.1186/s12885-024-11926-2 [pii]
AID - 11926 [pii]
AID - 10.1186/s12885-024-11926-2 [doi]
PST - epublish
SO  - BMC Cancer. 2024 Feb 12;24(1):192. doi: 10.1186/s12885-024-11926-2.